An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24746
Abstract: Myelodysplastic syndromes (MDSs) are characterized by ineffective hematopoiesis and an increased risk of transformation. Few effective therapies are available for lower risk MDS patients, especially after the failure of hypomethylating agents. MDS progenitor cells are… read more here.
Keywords: myelodysplastic syndromes; risk; lower risk; bortezomib ... See more keywords
Sickle cell disease in the Eastern Province of Saudi Arabia: Clinical and laboratory features
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26096
Abstract: proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50(1):37-45. 7. Romaguera JE, Fayad LE, McLaughlin P, et al. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate… read more here.
Keywords: cell; disease; lymphoblastic leukemia; bortezomib ... See more keywords
Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Medicine"
DOI: 10.1002/cam4.1246
Abstract: Outcomes have improved considerably in multiple myeloma (MM), but disparities among racial‐ethnic groups exist. Differences in utilization of novel therapeutics are likely contributing factors. We explored such differences from the SEER‐Medicare database. A utilization analysis… read more here.
Keywords: utilization; use; analysis; seer medicare ... See more keywords
Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort
Sign Up to like & getrecommendations! Published in 2020 at "Hematological Oncology"
DOI: 10.1002/hon.2736
Abstract: Multiple myeloma (MM) is the second most common blood cancer caused by the uncontrolled proliferation of clonal plasma cells. Despite recent advances in treatment, a majority of patients eventually relapse and die because of progressive… read more here.
Keywords: venetoclax; myeloma; bortezomib dexamethasone; bortezomib ... See more keywords
Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
Sign Up to like & getrecommendations! Published in 2022 at "Hematological Oncology"
DOI: 10.1002/hon.3045
Abstract: Mechanisms underlying interactions between a novel, clinically relevant circularized tumor necrosis factor‐related apoptosis inducing ligand (TRAIL) agonist, circularly permuted TRAIL (CPT) have been examined in multiple myeloma (MM) cells sensitive or resistant to bortezomib (BTZ).… read more here.
Keywords: necrosis factor; bortezomib; apoptosis; tumor necrosis ... See more keywords
Primärtherapie beim Multiplen Myelom
Sign Up to like & getrecommendations! Published in 2018 at "Der Internist"
DOI: 10.1007/s00108-018-0527-x
Abstract: ZusammenfassungDie Therapielandschaft des neu diagnostizierten multiplen Myeloms hat sich im Verlauf der letzten beiden Jahrzehnte entscheidend verändert. Die Einführung der Hochdosistherapie mit Melphalan und nachfolgender autologer Blutstammzelltransplantation führte zunächst zu einem verbesserten Gesamtüberleben bei jüngeren… read more here.
Keywords: mit; stem cell; transplantation; bortezomib ... See more keywords
Severe refractory CIDP: a case series of 10 patients treated with bortezomib
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Neurology"
DOI: 10.1007/s00415-017-8599-4
Abstract: Treatment options for patients with aggressive chronic inflammatory demyelinating neuropathy are limited and include the anti-CD20 antibody rituximab and the immunosuppressive regime cyclophosphamide. We aimed to investigate retrospectively the efficacy of bortezomib, a proteasome inhibitor… read more here.
Keywords: bortezomib; treatment; refractory cidp; case series ... See more keywords
Safety and comfort of domestic bortezomib injection in real-life experience
Sign Up to like & getrecommendations! Published in 2018 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-018-4155-8
Abstract: Despite novel agents, multiple myeloma is still an incurable disease, especially for elderly and frail patients, who are difficult to manage for concomitant comorbidities as the therapeutic options are limited and the response to chemotherapy… read more here.
Keywords: safety; bortezomib; life experience; real life ... See more keywords
An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line
Sign Up to like & getrecommendations! Published in 2019 at "Cytotechnology"
DOI: 10.1007/s10616-019-00362-x
Abstract: The phenomenon of acquired resistance to chemotherapeutic agents is a long-standing conundrum in cancer treatment. To help delineate drug resistance mechanisms and pave the way for the development of novel strategies, we generated a PC3… read more here.
Keywords: proteasome inhibitor; pc3 prostate; bortezomib; resistance ... See more keywords
Subcutaneous versus Intravenous Bortezomib Administration for Multiple Myeloma Patients: a Meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "Current Medical Science"
DOI: 10.1007/s11596-018-1844-y
Abstract: Bortezomib, the first potent therapeutic proteasome inhibitor, has been suggested as a standard care in patients with newly diagnosed and relapsed multiple myeloma (MM). However, evidence bearing on the efficacy and safety of subcutaneous (SC)… read more here.
Keywords: multiple myeloma; administration; bortezomib; meta analysis ... See more keywords
Effect of Lipoic Acid on the Biochemical Mechanisms of Resistance to Bortezomib in SH-SY5Y Neuroblastoma Cells
Sign Up to like & getrecommendations! Published in 2017 at "Molecular Neurobiology"
DOI: 10.1007/s12035-017-0575-6
Abstract: Neuroblastoma (NB) is an extracranial solid cancer and the most common cancer in infancy. Despite the standard treatment for NB is based on the combination of chemotherapeutic drugs such as doxorubicin, vincristine, cyclophosphamide, and cisplatin,… read more here.
Keywords: cell viability; effect; btz; stress ... See more keywords